Review highlights potential of cancer immunotherapy plus targeted therapy

“To support this goal and accelerate these efforts, changes in directions of research support and funding may be required,” co-authors Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology, and Jim Allison, Ph.D., chair of Immunology, said in the review. The review, titled “Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential,” covers the strengths and weaknesses of the two forms of therapy and notes how their combination could be particularly potent. …

Golgi trafficking controlled by G-proteins

The study is reported online April 9 in Developmental Cell. “Our work provides the first direct evidence that G proteins are signaling on membranes inside cells, not just at the cell surface as has been widely believed for several decades,” said Pradipta Ghosh, MD, associate professor and senior author…

Advocate uses genetic history to increase knowledge of hereditary cancer risk

The 33-year-old mother who has tested positive for the BRCA2 cancer gene is one of 12 people in her family over three generations linked to the gene or diagnosed with cancer. Now Koszegi is using her family’s genetic history to contribute to cancer research, prevention and treatment — with the aim of improving the quality of life for those facing hereditary risk…

Dual therapy’s 1-2 punch knocks out drug-resistant lung cancer

In experiments that combined the drug the patient had taken with a second compound that blocks off this newly discovered resistance pathway, the researchers were able to durably wipe out cancer cells in mice implanted with cells from the drug-resistant tumor. “Even in cancers that are responding to targeted therapy by conventional criteria, resistance is… Read More »

Personalized melanoma vaccines marshal powerful immune response

The tailor-made vaccines, given to three patients with advanced melanoma, appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors. The finding is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer. The research is reported April 2 in Science… Read More »

Strong grasp of immune response dynamics will enhance checkpoint blockade

“Identifying in advance who will benefit from treatment and developing combination therapies to improve and expand on current results will require us to decipher the dynamics of human immune response to tumors and their surrounding microenvironment,” said co-author Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at The University of Texas MD… Read More »

Small RNA plays big role suppressing cancer

Researchers at UC Davis have unraveled some of these relationships, identifying several interactions that directly impact liver and colon cancer. The work provides new insights into how miR-22 operates and could potentially lead to new cancer therapies. The study was published in the Journal of Biological Chemistry. “There are quite a few molecules present in… Read More »

Herpesvirus activates RIG-I receptor to evade body’s immune system

Led by Pinghui Feng, Ph.D., associate professor of molecular microbiology and immunology at the Keck School of Medicine of USC, the team found that herpesvirus proteins activate retinoic acid-induced gene I (RIG-I) by removal of an amino group from the glutamine and asparagine amino acids through a process called deamidation. RIG-I is a cellular receptor… Read More »